(Molecular Adsorbents Recirculating System, MARS)

Transcript

1 ,000 1,500 [1] B [2] [3] [4] [5] [6] [7] ( ) [8] MARS ( ) [9] MARS Stage [10] [11] [8] (Molecular Adsorbents Recirculating System, MARS)

2 MARS MARS 1. MARS : (1) 4. (MARS-flux) MARS [10] ( [12] (2) 20% ) (Human serum albumin) [9] 2. (bile acid) (bilirubin) (tryptophan) [14] 3. (ammonia) [15] (3) [16] (Low-flux) [10] [17] (MARS-flux) ( 1) [13] Molecular adsorbent recirculating system ( 13) 56

3 [18] 5. (Nitric Oxid) MARS (hyperdynamic) [19] MARS 6. (albumin bound toxin) [20] [21] (Aldosterone) (1) 1 [22,23] (2) A&B 8 ( MARS ) (3)MARS 1 (4)MARS 1 (MARS FLUX) 1 (diamars AC250) MARS 1 (diamars IE250) (diaflux) 1 5 ( 2) (5) 1 MARS (6) 1 1. (7) 2 (8) 20% 50 ml 12 25% 50 ml (9) 1000 ml 5 ( ml) (10) 25 cc 1 ( U/ml) (11) 75% MARS 4. MARS 1. (1)MARS 15 ( 15 ) (2) 57

4 2. MARS (3) MARS (6) Bilirubin Prothrombin time (5) diaflux (1) 3. (2) 4. MARS (3) Creatinine Urea BUN (4) Sodium Potassium Calcium (5) Total Protein Albumin I N R A m m o n i a B i l e a c i d s (4) 15 Cholinesterase SGOT SGPT γ-gt Alkaline phosphatase) 1. (1) (1) Hemoglobin Hematocrit A. 0.9% Leucocytes Platetets (2)C (CRP) B. 150 ml/min C. 58

5 D. E. F (2) A. B. 150 ml/min 1. C. ( NTG) 2. (3) 3. A. 150ml/min 4. B. 5. C. 6. D. (1) 9. (2) (3) % (4) MARS (pin pressure) 70% (pout pressure) (1) (3) A B 13. (2) (pin pressure) MARS (pout pressure) 450 mmhg 450 mmhg 0.9% 59

6 Schmidt R: A new procedure for the removal of protein bound drugs and toxins. ASAIO J Jul-Sep; 39(3): Awad SS, Swaniker F, Magee J, Punch j, Bartlett RH: Results of a phase I trial evaluating a liver support device utilizing 6~8 albumin dialysis. Surgery 2001; 130: ; 85: Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomburg G: Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12: S Stange J, Mitzner: A carrier-mediated transport of toxins in a hybrid membrane Safety barrier between a patients blood and a bioartificial liver. International Journal of Artificial Organs 1996; 19: Mitzner SR, Klammt S, Peszynski P, et al: Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating 1. system. Therapeutics Apheresis 2001; 5: (6) Stange J, Mitzner S, Klammt S, et al: Liver support by extracorporeal blood purification: A clinical observation. Liver Trans pl 2000; 6: Jalan R,Williams R: Acute-on-chronic liver failure. Pathophysiological basis of therapeutic options. Blood Purif 2002; 1997; 9(4): : Sen Williams, Jalan: The pathophysiological basis of acuteon-chronic liver failure. Liver 2002; 22(Suppl.2): Vivas S, Rodriguez M, Palacio MA, Linares A, Alonso JL, Rodrigo L: Presence of bacterial infection in bleeding cirrhotic 19. Hartleb M, Michielsen PP, Dziurkowska-Marek A: The role of patients is independently associated with early mortality and nitric oxide in portal hypertensive systemic and portal vascular pathology. Acta Gastroenterol Belg 1997; 60: failure to control bleeding. Dig Dis Sci 2001; 46: Venturini I, Corsi L, Avallone R, et al: Ammonia and endogenous 20. Mitzner S, Stange J, Dillmann A, Winkler RE, Michelsen A, benzodiazepine-like compounds in the pathogenesis of hepatic Knippel M, Schmidt R: Removal of protein-bound uremic encephalopathy. Scand J Gastroenterol 2001; 36: toxins by albumin dialysis. In vivo results. Nephrol Dial Transplant 1999; 14: A Bomzon A, Holt S, Moore K: Bile acids,oxidative stress and renal function in biliary obstruction. Semin Nephrol 1997; 17: 21. Gentilini P, Casini-Raggi V, Di Fiore G et al: Albumin improves the response to diuretics in patients with cirrhosis and ascites: 7. Helmy A, Jalan R, Newey DE, Johnston NR, Hayes PC, Webb Results of a randomized, controlled trial. J Hepatol 1999; 30: DJ: Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated 22. Roberts LR, Kamath PS: Ascites and hepatorenal syndrome: cirrhosis. Hepatology 2001; 33: Pathophysiology and management. Mayo Clin Proc ; 8. Sen S,Mookerjee, Davies NA,Williams R, Jalan R:The molecular adsorbents recirculating system(mars)in liver failure. 23. Schmidt LE, Sorensen VR, Svendsen LB, Larsen FS, Stange Aliment Pharmacol Ther 2002; 16(suppl 5): J, Hansen BA: Improvement of systemic vascular resistance 9. Sen S, Jalan R, Williams R: Liver failure basis of benefit of and arterial pressure in patients with acute or chronic liver therapy with the molecular adsorbents recirculating system. failure during treatment with the molecular adsorbent recycling system (MARS)[Abstract]. Hepatology 2000; 32(4Pt2): Int J Biochem Cell Biol 2003; 35(9): Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, 401A. 60